Overall Score

Scale Market Position

Mid-cap specialty pharma with a market cap of about $932M, which supports some commercial presence but not dominant scale.

Revenue per share of $4.61 and price-to-sales of 5.47 suggest a meaningful business footprint, though not a clear moat from scale alone.

Profitability Returns

Gross margin is very high at 95.0% and EBITDA margin is 70.0%, indicating strong unit economics.

Return on invested capital is 8.4% and return on capital employed is 8.8%, showing acceptable but not exceptional capital efficiency.

Balance Sheet Resilience

Leverage is meaningful with debt-to-equity at 1.24 and net debt to EBITDA at 7.06, which limits financial flexibility.

Liquidity is weak with a current ratio of 0.0, although operating cash flow coverage and interest coverage remain serviceable at 4.14x and 5.04x, respectively.

Competitive Advantage Durability

High gross margins and solid operating margins suggest some product-level pricing power, but the data does not show a clearly entrenched moat.

Dividend payout is elevated at 1.97x earnings, which may constrain reinvestment and long-term moat expansion.